AstraZeneca (AZN) Share Price, News & Analysis

Company Overview

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Key Stats

• Today's Range: £100.84 to £102.80
• 50-Day Range: 9,725 to £120.39
• 52-Week Range: 9,461 to £133.88
• Volume: 3.83 million shs
• Average Volume: 3.82 million shs
• Market Capitalization: £158.44 billion
• P/E Ratio: 3,245.08
• Dividend Yield: 2.29%
• Price Target: £104.12
• Consensus Rating: Moderate Buy

AstraZeneca Stock Analysis - MarketRank™

AstraZeneca scored higher than 29% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

AstraZeneca has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 6 buy ratings, 2 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

AstraZeneca has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of AstraZeneca is 3,245.08, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 112.73.

Price to Earnings Ratio vs. Sector

The P/E ratio of AstraZeneca is 3,245.08, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 87.11.

Price to Earnings Growth Ratio

AstraZeneca has a PEG Ratio of 0.86. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

AstraZeneca has a P/B Ratio of 4.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for AZN.

Dividend

• Score: 0.8 / 5
• Dividend Strength: Weak

Dividend Yield

AstraZeneca pays a meaningful dividend of 1.97%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

AstraZeneca does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of AstraZeneca is 7,428.57%. Payout ratios above 75% are not desirable because they may not be sustainable.

Sustainability and ESG

• Score: 4.0 / 5
• Environmental Score: -2.35

Short Interest

There is no current short interest data available for AZN.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: N/A

News Sentiment

AstraZeneca has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.

Search Interest

Only 25 people have searched for AZN on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added AstraZeneca to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, AstraZeneca insiders have bought more of their company's stock than they have sold. Specifically, they have bought £2,230,800 in company stock and sold GBX 0 in company stock.

Percentage Held by Insiders

Only 0.04% of the stock of AstraZeneca is held by insiders.

Percentage Held by Institutions

51.03% of the stock of AstraZeneca is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

AZN Stock Analysis - Frequently Asked Questions

How have AZN shares performed this year?

AstraZeneca's stock was trading at £106 at the beginning of 2024. Since then, AZN shares have decreased by 3.6% and is now trading at £102.22.
View the best growth stocks for 2024 here.

How do I buy shares of AstraZeneca?

Shares of AZN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of AstraZeneca own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AstraZeneca investors own include GSK (GSK), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Intel (INTC), Advanced Micro Devices (AMD) and Johnson & Johnson (JNJ).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Drug Manufacturers - General
• Sub-Industry: Pharmaceutical Products
• Current Symbol: LON:AZN
• CUSIP: N/A
• CIK: N/A
• Web: www.astrazeneca.com
• Phone: +44-20-73045000
• Fax: N/A
• Employees: 83,500
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: £104.12
• High Stock Price Target: £150
• Low Stock Price Target: GBX 74
• Potential Upside/Downside: +1.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.56
• Research Coverage: 9 Analysts

Profitability

• EPS (Most Recent Fiscal Year): GBX 3.15
• Trailing P/E Ratio: 3,245.08
• Forward P/E Ratio: 14.01
• P/E Growth: 0.86
• Net Income: £6.44 billion
• Net Margins: 13.11%
• Pretax Margin: N/A
• Return on Equity: 16.74%
• Return on Assets: 7.68%

Debt

• Debt-to-Equity Ratio: 84.97
• Current Ratio: 0.89
• Quick Ratio: 0.59

Sales & Book Value

• Annual Sales: £49.13 billion
• Price / Sales: 3.22
• Cash Flow: GBX 262.84 per share
• Price / Cash Flow: 38.89
• Book Value: GBX 2,549 per share
• Price / Book: 4.01

Miscellaneous

• Outstanding Shares: 1,550,000,000
• Free Float: N/A
• Market Cap: £158.44 billion
• Optionable: Not Optionable
• Beta: 0.17